BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 12810652)

  • 21. Transport of 7-ethyl-10-hydroxycamptothecin (SN-38) by breast cancer resistance protein ABCG2 in human lung cancer cells.
    Nakatomi K; Yoshikawa M; Oka M; Ikegami Y; Hayasaka S; Sano K; Shiozawa K; Kawabata S; Soda H; Ishikawa T; Tanabe S; Kohno S
    Biochem Biophys Res Commun; 2001 Nov; 288(4):827-32. PubMed ID: 11688982
    [TBL] [Abstract][Full Text] [Related]  

  • 22. BCRP/MXR/ABCP expression in topotecan-resistant human breast carcinoma cells.
    Yang CH; Schneider E; Kuo ML; Volk EL; Rocchi E; Chen YC
    Biochem Pharmacol; 2000 Sep; 60(6):831-7. PubMed ID: 10930538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chemosensitivity determinants of irinotecan hydrochloride in hepatocellular carcinoma cell lines.
    Takahata T; Ookawa K; Suto K; Tanaka M; Yano H; Nakashima O; Kojiro M; Tamura Y; Tateishi T; Sakata Y; Fukuda S
    Basic Clin Pharmacol Toxicol; 2008 Apr; 102(4):399-407. PubMed ID: 18248513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased expression of the breast cancer resistance protein (BCRP) in relapsed or refractory acute myeloid leukemia (AML).
    van den Heuvel-Eibrink MM; Wiemer EA; Prins A; Meijerink JP; Vossebeld PJ; van der Holt B; Pieters R; Sonneveld P
    Leukemia; 2002 May; 16(5):833-9. PubMed ID: 11986944
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of function of three ABC drug transporters, P-glycoprotein (ABCB1), mitoxantrone resistance protein (ABCG2) and multidrug resistance protein 1 (ABCC1) by tetrahydrocurcumin, a major metabolite of curcumin.
    Limtrakul P; Chearwae W; Shukla S; Phisalphong C; Ambudkar SV
    Mol Cell Biochem; 2007 Feb; 296(1-2):85-95. PubMed ID: 16960658
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of ABC-cassette transporters (MDR1, MRP1, BCRP) in the development of primary and acquired multiple drug resistance in patients with early and metastatic breast cancer.
    Kovalev AA; Tsvetaeva DA; Grudinskaja TV
    Exp Oncol; 2013 Dec; 35(4):287-90. PubMed ID: 24382439
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Interactions of cyclosporin a with breast cancer resistance protein.
    Xia CQ; Liu N; Miwa GT; Gan LS
    Drug Metab Dispos; 2007 Apr; 35(4):576-82. PubMed ID: 17220244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel camptothecin analogues that circumvent ABCG2-associated drug resistance in human tumor cells.
    Yoshikawa M; Ikegami Y; Hayasaka S; Ishii K; Ito A; Sano K; Suzuki T; Togawa T; Yoshida H; Soda H; Oka M; Kohno S; Sawada S; Ishikawa T; Tanabe S
    Int J Cancer; 2004 Jul; 110(6):921-7. PubMed ID: 15170677
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of efflux transporter ABCG2/BCRP does not restore mitoxantrone sensitivity in irinotecan-selected human leukemia CPT-K5 cells: evidence for multifactorial multidrug resistance.
    Su Y; Lee SH; Sinko PJ
    Eur J Pharm Sci; 2006 Oct; 29(2):102-10. PubMed ID: 16844360
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein.
    Wang X; Nitanda T; Shi M; Okamoto M; Furukawa T; Sugimoto Y; Akiyama S; Baba M
    Biochem Pharmacol; 2004 Oct; 68(7):1363-70. PubMed ID: 15345326
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: potential role for breast cancer resistance protein in clinical drug-drug interactions.
    Breedveld P; Zelcer N; Pluim D; Sönmezer O; Tibben MM; Beijnen JH; Schinkel AH; van Tellingen O; Borst P; Schellens JH
    Cancer Res; 2004 Aug; 64(16):5804-11. PubMed ID: 15313923
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of drug efflux proteins and topoisomerase I mutations on the camptothecin analogue gimatecan.
    Gounder MK; Nazar AS; Saleem A; Pungaliya P; Kulkarni D; Versace R; Rubin EH
    Invest New Drugs; 2008 Jun; 26(3):205-13. PubMed ID: 17943230
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mouse breast cancer resistance protein (Bcrp1/Abcg2) mediates etoposide resistance and transport, but etoposide oral availability is limited primarily by P-glycoprotein.
    Allen JD; Van Dort SC; Buitelaar M; van Tellingen O; Schinkel AH
    Cancer Res; 2003 Mar; 63(6):1339-44. PubMed ID: 12649196
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gefitinib ("Iressa", ZD1839), an epidermal growth factor receptor tyrosine kinase inhibitor, reverses breast cancer resistance protein/ABCG2-mediated drug resistance.
    Nakamura Y; Oka M; Soda H; Shiozawa K; Yoshikawa M; Itoh A; Ikegami Y; Tsurutani J; Nakatomi K; Kitazaki T; Doi S; Yoshida H; Kohno S
    Cancer Res; 2005 Feb; 65(4):1541-6. PubMed ID: 15735043
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transport mechanism-based drug molecular design: novel camptothecin analogues to circumvent ABCG2-associated drug resistance of human tumor cells.
    Ishikawa T; Ikegami Y; Sano K; Nakagawa H; Sawada S
    Curr Pharm Des; 2006; 12(3):313-25. PubMed ID: 16454746
    [TBL] [Abstract][Full Text] [Related]  

  • 36. C421A polymorphism in the human breast cancer resistance protein gene is associated with low expression of Q141K protein and low-level drug resistance.
    Imai Y; Nakane M; Kage K; Tsukahara S; Ishikawa E; Tsuruo T; Miki Y; Sugimoto Y
    Mol Cancer Ther; 2002 Jun; 1(8):611-6. PubMed ID: 12479221
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transport of topoisomerase I inhibitors by the breast cancer resistance protein. Potential clinical implications.
    Schellens JH; Maliepaard M; Scheper RJ; Scheffer GL; Jonker JW; Smit JW; Beijnen JH; Schinkel AH
    Ann N Y Acad Sci; 2000; 922():188-94. PubMed ID: 11193894
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Modulation of P-glycoprotein but not MRP1- or BCRP-mediated drug resistance by LY335979.
    Shepard RL; Cao J; Starling JJ; Dantzig AH
    Int J Cancer; 2003 Jan; 103(1):121-5. PubMed ID: 12455064
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multidrug resistance mediated by the breast cancer resistance protein BCRP (ABCG2).
    Doyle L; Ross DD
    Oncogene; 2003 Oct; 22(47):7340-58. PubMed ID: 14576842
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overexpression of wild-type breast cancer resistance protein mediates methotrexate resistance.
    Volk EL; Farley KM; Wu Y; Li F; Robey RW; Schneider E
    Cancer Res; 2002 Sep; 62(17):5035-40. PubMed ID: 12208758
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.